Chromatin licenses gene stacking technology to Syngenta Biotechnology

NewsGuard 100/100 Score

Chromatin Inc. has announced that it has entered into a research and commercial license agreement with Syngenta Biotechnology Inc. for Chromatin's proprietary gene stacking technology.

Chromatin has developed a novel approach to gene stacking, using the plant's own DNA to deliver several genes on a mini-chromosome. Under the agreement, Syngenta has obtained non-exclusive rights to use Chromatin ' s gene stacking technology for trait genes in corn and soybeans.

“Growers need increasingly more sophisticated tools to meet the demands on the agriculture market, and stacked traits along with improved seed germplasm will be instrumental, ” said Roger Kemble, Head of Syngenta Crop Genetics Research. “ We will evaluate this technology in combination with our own innovative research programs and strong pipeline as part of our intense commitment to speed delivery of products to market. ”

“Syngenta is a leading agribusiness company committed to developing crops that meet multiple needs. Chromatin is pleased to partner with Syngenta, whose trait gene inventory and crop production programs make them an ideal partner for us, ” said Daphne Preuss, Chromatin's Chief Scientific Officer and President.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles